Coverage
Filings
| Filing | Date |
|---|---|
| GSK announces intention to sell shares in Haleon | 16 Jan 2024 |
| Nucala approved in China for use in severe asthma | 10 Jan 2024 |
| GSK enters agreement to acquire Aiolos Bio | 9 Jan 2024 |
| Total Voting Rights | 2 Jan 2024 |
| Director/PDMR Shareholding | 21 Dec 2023 |
| Publication of EMTN Suppl.Prospcts | 20 Dec 2023 |
| Jemperli plus Zejula Trial Meets Endpoint | 18 Dec 2023 |
| Director/PDMR Shareholding |
GSK said Monday it has appointed Chief Commercial Officer Luke Miels as its next chief executive, succeeding Dame Emma Walmsley.
GSK PLC announced plans to invest $30 billion in the United States over the next five years to boost its research, development, and manufacturing capabilities.
GSK said on Monday that the U.S. Food and Drug Administration has accepted for review its application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to at-risk adults aged 18 to 49.
| 13 Dec 2023 |
| Japan accepts Arexvy filing for at risk adults | 12 Dec 2023 |
| Jemperli plus chemotherapy EU authorisation | 11 Dec 2023 |
| GSK publishes provisional 2024 dividend dates | 4 Dec 2023 |
| Total Voting Rights | 1 Dec 2023 |